Format

Send to

Choose Destination
Int J Mol Sci. 2017 Feb 14;18(2). pii: E404. doi: 10.3390/ijms18020404.

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.

Author information

1
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China. likai.19870816@163.com.
2
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China. qs1996neptune@163.com.
3
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China. www.candychen@foxmail.com.
4
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China. kigo@hit.edu.cn.
5
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China. shiming@hit.edu.cn.

Abstract

Malignant cancers employ diverse and intricate immune evasion strategies, which lead to inadequately effective responses of many clinical cancer therapies. However, emerging data suggest that activation of the tolerant innate immune system in cancer patients is able, at least partially, to counteract tumor-induced immunosuppression, which indicates triggering of the innate immune response as a novel immunotherapeutic strategy may result in improved therapeutic outcomes for cancer patients. The promising innate immune targets include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Stimulator of Interferon Genes (STING). This review discusses the antitumor properties of TLRs, RLRs, and STING-mediated innate immune pathways, as well as the promising innate immune targets for potential application in cancer immunotherapy.

KEYWORDS:

RIG-I-like Receptors; Stimulator of Interferon Genes; Toll-like Receptors; cancer immunotherapy; innate immunity

PMID:
28216575
PMCID:
PMC5343938
DOI:
10.3390/ijms18020404
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center